# **Cyient DLM**

Electronics | India

**IPO** | 26 June 2023



# **Electronic Manufacturing Services & Solutions**

### **About the Company**

Cyient DLM Limited is engaged in the business of Electronic Manufacturing Services (EMS) and solutions. The company provides EMS as Build to Print (B2P) and Build to Specification (B2S) services. In case of B2P solutions, the company provides agile and flexible manufacturing services for clients with design for their products. B2S services involve designing the product based on the specifications provided by the client and manufacturing the product. The company has 3 manufacturing facilities in Mysuru, Hyderabad and Bengaluru, with a total area of 229,061 sq. ft. Cyient DLM has long-term relationships with marquee customers such as Honeywell International Inc., Thales Global Services S.A.S, ABB Inc, Bharat Electronics Ltd and Molbio Diagnostics Pvt Ltd, having had an average relationship of over 11 years as on Mar'23. The company is coming up with an IPO comprising entirely of fresh issue of 22.3mn shares, aggregating to Rs5.92bn at upper price band.

### **Strong Capabilities across Sectors**

Cyient DLM leverages its capabilities across sectors and is the qualified supplier to global Original Equipment Manufacturers (OEMs) in the aerospace and defence, medical technology and industrial sectors. It implements a 'Low volume, high mix' (IVHM) contract manufacturing setup which typically has a very high emphasis on quality and customization. The company has over 22 years of experience in developing high mix, low-to-medium volume complex system.

# **Diverse Array of Products & Services**

The company's solutions comprise: *i) Printed Circuit Board (PCB) assembly* which involves the process of connecting electronic components onto PCB. *ii) Cable Harnesses* solutions involve the process of assembly of electrical cables or wires. *iii) Box Builds* also known as systems integration, can be anything from a simple PCBA housed in a small enclosure, to a cabinet housing a complex electromechanical system, ranging from very simple to complex devices with a wide range of applications. These solutions are utilised in safety critical systems such as cockpits, inflight systems, landing systems, and medical diagnostic equipment. Cyient DLM also offers several value added and after-market services to its customers, such as obsolescence management, new product introduction, value engineering, sustenance engineering and logistics and supply chain management.

### **Financials in Brief**

During FY21-23, its revenue/EBITDA/PAT has grown at a CAGR of 15%/18%/4%. For FY23, its revenue was at Rs8,320mn while EBITDA stood at Rs878mn. EBIDTA margin has consistently remained in the 10-12% range over FY21-23. PAT during FY21, FY22 and FY23 stood at Rs293mn, Rs398mn and Rs317mn respectively. Return ratios are strong with average RoE/RoCE of 48%/13.4% during FY21-23. Average Net Asset Turnover during FY21-23 was at 4.3x.

## **Our View**

On FY23 annualized financials, the IPO is valued at 66.2x P/E, 25.6x EV/EBITDA and 2.7x EV/Sales, at the upper price band. The EMS market globally is witnessing a strong growth trajectory. India's EMS market contributes 2.2% (\$20bn) of the global EMS market in 2022 and it is the fastest growing among all countries at a CAGR of 32.3%. It is expected to contribute 7% (\$80bn) of the global EMS market in 2026 which will aid the company to grow further. Considering the strong business prospects, healthy financials, diversified product mix, tailwinds on the back of solutions-oriented approach, client-focused service and track record of reliability, we recommend SUBSCRIBE to the issue.

IPO Details	
Price Band (Rs)	250-265
Face Value (Rs)	10
Issue Open/Closing Date	27-June-23/30-June-23
Fresh Issues (mn)	22.3
OFS (mn)	-
Total Issue (mn)	22.3
Minimum Bid Qty. (Nos)	56
Issue Size (Rs bn)*	5.92
QIB / HNI / Retail	75%/15%/10%
Implied Market Cap (Rs bn)*	21.0
*At higher band	

#### Object of the Issue

- Funding incremental working capital requirement
- Funding capex.
- Repayment/Prepayment of debt.
- Achieving inorganic growth through acquisitions.
- General corporate purposes.

#### **Key Risk**

- Dependent on the sale of products to certain key customers.
- Failure to compete effectively in the highly competitive EMS industry.
- Problems arising related to product designs.
- Dependent on third party suppliers for raw materials and components.
- Foreign exchange fluctuations.

Shareholding (%)	Pre-Issue	Post-Issue	
Promoters	92.8	66.7	
Others	7.2	33.3	

#### **Key Financials**

110) I III all all all all all all all all a			
(Rs mn)	FY21	FY22	FY23
Revenue	6,280	7,205	8,320
EBITDA	459	840	878
EBITDA Margin (%)	7.3	11.7	10.6
PAT	118	398	317
PAT Margin (%)	1.9	5.5	3.8
EPS (Rs)	1.5	5.0	4.0
P/E (x)	177.8	52.8	66.2
EV/EBITDA (x)	50.1	27.0	25.6
EV/Sales (x)	3.7	3.2	2.7
Net Worth	377	771	1,979
RoE (%)	31.4	51.6	16.0
Gross Debt	2,338	2,932	3,145
Net Block	1,826	1,692	1,579
Net Asset Turnover (x)	3.4	4.3	5.3


Source: RHP

Research Analyst: Sumeet Shah

Contact : (022) 41681371 Email : sumeet.shah@relianceada.com


# **Industry Data**

**Exhibit 1: Global Electronics Industry (\$bn)** 




Source: RHP, Statista, New Venture Research, F&S Report

Exhibit 3: Global Electronics Manufacturing Market - Split between In-House & EMS (\$bn)




Source: RHP, Statista, F&S Report

Exhibit 5: Global EMS Market – Segmentation by HVLM Vs. LVHM (\$bn)




Source: RHP, ELCINA, F&S Report

Exhibit 2: Per Capita Consumption of Electronics in Major Economies (\$)




Source: RHP, IMF, F&S Report

Exhibit 4: Global EMS Market – Segmentation by ODM Vs. CM (\$bn)




Source: RHP, ELCINA, F&S Report

Exhibit 6: Global EMS Market - Segmentation by Manufacturing Location CY26E (%)




Source: RHP, F&S Report

Exhibit 8: Total Electronics Market, India (Rs bn)




Source: RHP, MeitY, ELCINA, F&S Report

Exhibit 10: Indian Domestic Electronics Production Market - Split between In-House Manufacturing and EMS (Rs bn)




Source: RHP, IMF, RBI, F&S Report

Exhibit 7: Global EMS Market - Segmentation by End-User Industries CY26E (%)




Source: RHP, F&S Report

Exhibit 9: Domestic Electronics Consumption Market, India (Rs bn)



Source: RHP, MeitY, ELCINA, F&S Report


Exhibit 11: Indian EMS Market Segmentation by ODM Vs. CM (Rs bn)



Source: RHP, ELCINA, F&S Report




Exhibit 12: Indian EMS Market - Segmentation by End-User Industries FY27E (%)



Source: RHP, MeitY, ELCINA, F&S Report


# **Company Data**

# Exhibit 13: Revenue (Rs mn)




Source: RHP

Exhibit 14: Revenue Industry-Wise (Rs mn)



Source: RHP

# Exhibit 15: B2P & B2S (Rs mn)




Source: RHP

**Exhibit 16: Products and Services** 

\_\_\_\_







Source: RHP



# **Disclaimer:**

Reliance Securities Limited (RSL), the broking arm of Reliance Capital is one of the India's leading retail broking houses. Reliance Capital is amongst India's leading and most valuable financial services companies in the private sector. Reliance Capital has interests in asset management and mutual funds, life and general insurance, commercial finance, equities and commodities broking, wealth management services, distribution of financial products, private equity, asset reconstruction, proprietary investments and other activities in financial services. The list of associates of RSL is available on the website www.reliancecapital.co.in. RSL is registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014

General Disclaimers: This Research Report (hereinafter called 'Report') is prepared and distributed by RSL for information purposes only. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through RSL nor any solicitation or offering of any investment /trading opportunity on behalf of the issuer(s) of the respective security(ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by RSL to be reliable. RSL or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of RSL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report.

Risks: Trading and investment in securities are subject to market risks. There are no assurances or guarantees that the objectives of any of trading / investment in securities will be achieved. The trades/ investments referred to herein may not be suitable to all categories of traders/investors. The names of securities mentioned herein do not in any manner indicate their prospects or returns. The value of securities referred to herein may be adversely affected by the performance or otherwise of the respective issuer companies, changes in the market conditions, micro and macro factors and forces affecting capital markets like interest rate risk, credit risk, liquidity risk and reinvestment risk. Derivative products may also be affected by various risks including but not limited to counter party risk, market risk, valuation risk, liquidity risk and other risks. Besides the price of the underlying asset, volatility, tenor and interest rates may affect the pricing of derivatives.

Disclaimers in respect of jurisdiction: The possession, circulation and/or distribution of this Report may be restricted or regulated in certain jurisdictions by appropriate laws. No action has been or will be taken by RSL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. RSL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to RSL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India.

**Disclosure of Interest:** The research analysts who have prepared this Report hereby certify that the views /opinions expressed in this Report are their personal independent views/opinions in respect of the securities and their respective issuers. None of RSL, research analysts, or their relatives had any known direct /indirect material conflict of interest including any long/short position(s) in any specific security on which views/opinions have been made in this Report, during its preparation. RSL's Associates may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report. RSL, its Associates, the research analysts, or their relatives might have financial interest in the issuer company(ies) of the said securities. RSL or its Associates may have received a compensation from the said issuer company(ies) in last 12 months for the brokerage services.RSL, its Associates, the research analysts or their relatives have not received any compensation or other benefits directly or indirectly from the said issuer company(ies) or any third party in last 12 months in any respect whatsoever for preparation of this report.

The research analysts has served as an officer, director or employee of the said issuer company(ies)?: No

RSL, its Associates, the research analysts or their relatives holds ownership of 1% or more, in respect of the said issuer company(ies).?: No

**Copyright:** The copyright in this Report belongs exclusively to RSL. This Report shall only be read by those persons to whom it has been delivered. No reprinting, reproduction, copying, distribution of this Report in any manner whatsoever, in whole or in part, is permitted without the prior express written consent of RSL.

RSL's activities were neither suspended nor have defaulted with any stock exchange with whom RSL is registered. Further, there does not exist any material adverse order/judgments/ strictures assessed by any regulatory, government or public authority or agency or any law enforcing agency in last three years. Further, there does not exist any material enquiry of whatsoever nature instituted or pending against RSL as on the date of this Report.

Important These disclaimers, risks and other disclosures must be read in conjunction with the information / opinions / views of which they form part of.

RSL CIN: U65990MH2005PLC154052. SEBI registration no. (Stock Broker: INZ000172433, Depository Participants: CDSL IN-DP-257-2016 IN-DP-NSDL-363-2013, Research Analyst: INH000002384); AMFI ARN No.29889.